Association of Naturalistic Administration of Cannabis Flower and Concentrates With Intoxication and Impairment
- PMID: 32520316
- PMCID: PMC7287943
- DOI: 10.1001/jamapsychiatry.2020.0927
Association of Naturalistic Administration of Cannabis Flower and Concentrates With Intoxication and Impairment
Abstract
Importance: The rapidly growing legal cannabis market includes new and highly potent products, the effects of which, to our knowledge, have not previously been examined in biobehavioral research studies because of federal restrictions on cannabis research.
Objective: To use federally compatible, observational methods to study high-∆9-tetrahydrocannabinol (THC) legal market forms of cannabis.
Design, setting, and participants: In this cohort study with a between-groups design that was conducted in a community and university setting, cannabis flower users and concentrate users were randomly assigned to higher- vs lower-THC products within user groups. Participants completed a baseline and an experimental mobile laboratory assessment that included 3 points: before, immediately after, and 1 hour after ad libitum legal market flower and concentrate use. Of the 133 individuals enrolled and assessed, 55 regular flower cannabis users (41.4%) and 66 regular concentrate cannabis users (49.6%) complied with the study's cannabis use instructions and had complete data across primary outcomes.
Exposures: Flower users were randomly assigned to use either 16% or 24% THC flower and concentrate users were randomly assigned to use either 70% or 90% THC concentrate that they purchased from a dispensary.
Main outcomes and measures: Primary outcome measures included plasma cannabinoids, subjective drug intoxication, and neurobehavioral tasks testing attention, memory, inhibitory control, and balance.
Results: A total of 121 participants completed the study for analysis: 55 flower users (mean [SD] age, 28.8 [8.1] years; 25 women [46%]) and 66 concentrate users (mean [SD] age, 28.3 [10.4] years; 30 women [45%]). Concentrate users compared with flower users exhibited higher plasma THC levels and 11-hydroxyΔ9-THC (THC's active metabolite) across all points. After ad libitum cannabis administration, mean plasma THC levels were 0.32 (SE = 0.43) μg/mL in concentrate users (to convert to millimoles per liter, multiply by 3.18) and 0.14 (SE = 0.16) μg/mL in flower users. Most neurobehavioral measures were not altered by short-term cannabis consumption. However, delayed verbal memory (F1,203 = 32.31; P < .001) and balance function (F1,203 = 18.88; P < .001) were impaired after use. Differing outcomes for the type of product (flower vs concentrate) or potency within products were not observed.
Conclusions and relevance: This study provides information about the association of pharmacological and neurobehavioral outcomes with legal market cannabis. Short-term use of concentrates was associated with higher levels of THC exposure. Across forms of cannabis and potencies, users' domains of verbal memory and proprioception-focused postural stability were primarily associated with THC administration.
Conflict of interest statement
Figures
Similar articles
-
A naturalistic study of orally administered vs. inhaled legal market cannabis: cannabinoids exposure, intoxication, and impairment.Psychopharmacology (Berl). 2022 Feb;239(2):385-397. doi: 10.1007/s00213-021-06007-2. Epub 2021 Oct 27. Psychopharmacology (Berl). 2022. PMID: 34708254
-
Investigating sex differences in acute intoxication and verbal memory errors after ad libitum cannabis concentrate use.Drug Alcohol Depend. 2021 Jun 1;223:108718. doi: 10.1016/j.drugalcdep.2021.108718. Epub 2021 Apr 20. Drug Alcohol Depend. 2021. PMID: 33866072 Free PMC article.
-
Effects of cannabidiol in cannabis flower: Implications for harm reduction.Addict Biol. 2022 Jan;27(1):e13092. doi: 10.1111/adb.13092. Epub 2021 Aug 31. Addict Biol. 2022. PMID: 34467598 Free PMC article. Clinical Trial.
-
Advancing the science on cannabis concentrates and behavioural health.Drug Alcohol Rev. 2021 Sep;40(6):900-913. doi: 10.1111/dar.13281. Epub 2021 Mar 30. Drug Alcohol Rev. 2021. PMID: 33783029 Free PMC article. Review.
-
Tolerability of High-Dose Oral Δ9-THC: Implications for Human Laboratory Study Design.Cannabis Cannabinoid Res. 2024 Apr;9(2):437-448. doi: 10.1089/can.2023.0209. Epub 2024 Feb 19. Cannabis Cannabinoid Res. 2024. PMID: 38377580 Review.
Cited by
-
Edible cannabis for chronic low back pain: associations with pain, mood, and intoxication.Front Pharmacol. 2024 Sep 24;15:1464005. doi: 10.3389/fphar.2024.1464005. eCollection 2024. Front Pharmacol. 2024. PMID: 39380911 Free PMC article.
-
Dose Estimation Utility in a Population Pharmacokinetic Analysis of Inhaled Δ9-Tetrahydrocannabinol Cannabis Market Products in Occasional and Daily Users.Ther Drug Monit. 2024 Oct 1;46(5):672-680. doi: 10.1097/FTD.0000000000001224. Epub 2024 May 23. Ther Drug Monit. 2024. PMID: 39235358 Free PMC article.
-
The Reddit cannabis subjective highness rating scale: Applying computational social science to explore psychological and environmental correlates of naturalistic cannabis use.PLoS One. 2024 Jun 25;19(6):e0300290. doi: 10.1371/journal.pone.0300290. eCollection 2024. PLoS One. 2024. PMID: 38917066 Free PMC article.
-
Human laboratory models of reward in substance use disorder.Pharmacol Biochem Behav. 2024 Aug;241:173803. doi: 10.1016/j.pbb.2024.173803. Epub 2024 Jun 4. Pharmacol Biochem Behav. 2024. PMID: 38843997 Review.
-
Acute and Extended Anxiolytic Effects of Cannabidiol in Cannabis Flower: A Quasi-Experimental ad libitum Use Study.Cannabis Cannabinoid Res. 2024 Aug;9(4):1015-1027. doi: 10.1089/can.2023.0187. Epub 2024 Jan 22. Cannabis Cannabinoid Res. 2024. PMID: 38252547 Clinical Trial.
References
-
- Orens A, Light M, Lewandowski B, Rowberry J, Saloga C 2017 market update. Accessed August 20, 2018. https://www.colorado.gov/pacific/sites/default/files/MED%20Demand%20and%...
